Literature DB >> 16395413

Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk.

Ginés Escolar1, Maribel Díaz-Ricart, Esther Gomez-Gil, Montserrat Serra, Cristobal Gasto, Jordi Bozzo, Ana Maria Galán.   

Abstract

Cardiovascular disease and major depression are highly prevalent disorders in our society. Evidence has been found that confirms a reciprocal relationship between mechanisms of depression and those of cardiovascular pathology. This possible feedback between both pathologies is a subject of great concern. In recent years some studies suggest that platelets and serotonergic mechanisms could be involved in both conditions. The present review seeks a better understanding of the mechanisms that could link depression with an enhanced cardiovascular risk. Copyright (c) 2005 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16395413     DOI: 10.1358/dot.2005.41.11.904727

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  4 in total

Review 1.  Antibodies against G-protein coupled receptors: novel uses in screening and drug development.

Authors:  Achla Gupta; Andrea S Heimann; Ivone Gomes; Lakshmi A Devi
Journal:  Comb Chem High Throughput Screen       Date:  2008-07       Impact factor: 1.339

2.  Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression.

Authors:  Montserrat Serra-Millàs; Irene López-Vílchez; Víctor Navarro; Ana-María Galán; Ginés Escolar; Rafael Penadés; Rosa Catalán; Lourdes Fañanás; Bárbara Arias; Cristóbal Gastó
Journal:  Psychopharmacology (Berl)       Date:  2011-02-11       Impact factor: 4.530

3.  Depression in vascular pathologies: the neurologist's point of view.

Authors:  Rita Moretti; Elena Bernobich; Francesca Esposito; Paola Torre; Rodolfo M Antonello; Luisa De Angelis; Giuseppe Bellini
Journal:  Vasc Health Risk Manag       Date:  2011-07-12

4.  Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men.

Authors:  Agorastos Agorastos; Michael Kellner; Oliver Stiedl; Christoph Muhtz; Klaus Wiedemann; Cüneyt Demiralay
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-11       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.